朱友琦,白明,苏昱润

• 1:兰州大学第一医院(第一临床医学院)心内科

摘要(Abstract)：

高血压与糖尿病被认为是导致心血管病发病率与死亡率最高的两大共病。糖尿病是一种病因复杂的代谢性疾病，尽管近年来其发病机制与治疗手段取得了显著进展，仍存在诸多未解问题。研究显示，交感神经系统过度激活在糖尿病的发生与发展中发挥关键作用。经皮去肾神经术（RDN）可有效降低交感神经活性，因此其在糖尿病管理中的潜在应用逐渐引起关注。近年来，RDN因在难治性高血压治疗中的疗效而受到肯定，越来越多研究开始探索其在糖尿病患者中的应用价值及潜在获益。本文将重点综述交感神经激活在糖尿病中的作用机制，RDN在糖尿病管理中的研究进展，并展望其未来的临床应用前景。

关键词(KeyWords)： 经皮去肾神经术;糖尿病;交感神经活性;高血压

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 朱友琦,白明,苏昱润

参考文献(References)：

• [1]Butler R,MacDonald TM,Struthers AD,et al.The clinical implications of diabetic heart disease[J].Eur Heart J,1998,19(11):1617-1627.DOI:10.1053/euhj.1998.1284.
• [2]Castro Torres Y,Katholi RE.Novel treatment approaches in hypertensive type 2 diabetic patients[J].World J Diabetes,2014,5(4):536-545.DOI:10.4239/wjd.v5.i4.536.
• [3]Maraschin Jde F,Murussi N,Witter V,et al.Diabetes mellitus classification[J].Arq Bras Cardiol,2010,95(2):e40-e46.DOI:10.1590/s0066-782x2010001200025.
• [4] Kalyani RR,Neumiller JJ,Maruthur NM,et al.Diagnosis and treatment of type 2 diabetes in adults:a review[J].JAMA,2025,334(11):984-1002.DOI:10.1001/jama.2025.5956.
• [5]Goff DC Jr,Gerstein HC,Ginsberg HN,et al.Prevention of cardiovascular disease in persons with type 2 diabetes mellitus:current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes(ACCORD)trial[J].Am J Cardiol,2007,99(12A):4i-20i.DOI:10.1016/j.amjcard.2007.03.002.
• [6]Buse JB,Ginsberg HN,Bakris GL,et aI.Primary prevention of cardiovascular diseases in people with diabetes mellitus:a scientific statement from the American Heart Association and the American Diabetes Association[J].Circulation,2007,115(1):114-126.DOI:10.1161/CIRCULATIONAHA.106.179294.
• [7] Sardu C,Marfella R,Santulli G.Impact of diabetes mellitus on the clinical response to cardiac re synchronization therapy in elderly people[J].J Cardiovasc Transl Res,2014,7(3):362-368.DOI:10.1007/s12265-014-9545-9.
• [8]Roper NA,Bilous RW,Kelly WF,et al.Excess mortality in a population with diabetes and the impact of material deprivation:longitudinal,population based study[J].BMJ,2001,322(7299):1389-1393.DOI:10.1136/bmj.322.7299.1389.
• [9]Whiting DR,Guariguata L,Weil C,et al.IDF diabetes atlas:global estimates of the prevalence of diabetes for 2011 and 2030[J].Diabetes Res Clin Pract,2011,94(3):311-321.DOI:10.1016/j.diabres.2011.10.029.
• [10]Kandzari DE,Mahfoud F,Townsend RR,et al.Long-term safety and efficacy of renal denervation:24-month results from the SPYRAL HTN-ON MED trial[J].Circ Cardiovasc Interv,2025,18(7):e015194.DOI:10.1161/CIRCINTERVENTIONS.12 5.015194.
• [11] Barbato E,Azizi M,Schmieder RE,et al.Renal denervation in the management of hypertension in adults.A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions(EAPCI)[J].EuroIntervention,2023,18(15):1227-1243.DOI:10.4244/eij-d-22-00723.
• [12] McCarthy CP,Bruno RM,Rahimi K,et al.What is new and different in the 2024 European Society of Cardiology Guidelines for the management of elevated blood pressure and hypertension?[J].Hypertension,2025,82(3):432-444.DOI:10.1161/HYPERTENSIONAHA.124.24173.
• [13]Lambert GW,Straznicky NE,Lambert EA,et al.Sympathetic nervous activation in obesity and the metabolic syndrome--causes,consequences and therapeutic implications[J].Pharmacol Ther,2010,126(2):159-172.DOI:10.1016/j.pharmthera.2010.02.002.
• [14]Thorp AA,Schlaich MP.Relevance of sympathetic nervous system activation in obesity and metabolic syndrome[J].J Diabetes Res,2015,2015:3415 83.DOI:10.1155/2015/341583.
• [15]Hering D,Esler MD,Schlaich MP.Effects of renal denervation on insulin resistance[J].Expert Rev Cardiovasc Ther,2012,10(11):1381-1386.DOI:10.1586/erc.12.140.
• [16]Kuehl M,Stevens MJ.Cardiovascular autonomic neuropathies as complications of diabetes mellitus[J].Nat Rev Endocrinol,2012,8(7):405-416.DOI:10.1038/nrendo.2012.21.
• [17] Rowaiye OO,Jankowska EA,Ponikowska B.Baroreceptor sensitivity and diabetes mellitus[J].Cardiol J,2013,20(5):453-463.DOI:10.5603/CJ.2013.0130.
• [18]Chon KH,Yang B,Posada-Quintero HF,et al.A novel quantitative method for diabetic cardiac autonomic neuropathy assessment in type 1 diabetic mice[J].J Diabetes Sci Technol,2014,8(6):1157-1167.DOI:10.1177/1932296814545669.
• [19]Iyngkaran P,Anavekar N,Majoni W,et al.The role and management of sympathetic overactivity in cardiovascular and renal complications of diabetes[J].Diabetes Metab,2013,39(4):290-298.DOI:10.1016/j.diabet.2013.05.002.
• [20]Luippold G,Beilharz M,Mühlbauer B.Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats[J].Nephrol Dial Transplant,2004,19(2):342-347.DOI:10.1093/ndt/gfg5 84.
• [21]Mahfoud F,Schlaich M,Kindermann I,et al.E ffect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension:a pilot study[J].Circulation,2011,123(18):1940-1946.DOI:10.1161/circulationaha.110.991869.
• [22]Witkowski A,Prejbisz A,Florczak E,et al.Effects of renal sympathetic denervation on blood pressure,sleep apnea course,and glycemic control in patients with resistant hypertension and sleep apnea[J].Hypertension,2011,58(4):559-565.DOI:10.116 1/HYPERTENSIONAHA.111.173799.
• [23]Schlaich MP,Straznicky N,Grima M,et al.Renal denervation:a potential new treatment modality for polycystic ovary syndrome?[J].J Hypertens,2011,29(5):991-996.DOI:10.1097/HJH.0b013e328344db3a.
• [24]Schaan BD,Irigoyen MC,Lacchini S,et al.Sympathetic modulation of the renal glucose transporter GLUT2 in diabetic rats[J].Auton Neurosci,2005,117(1):54-61.DOI:10.1016/j.autneu.2004.11.001.
• [25]Bikhazi AB,Azar ST,Birbari AE,et al.Characterization of insulin-resistance:role of receptor alteration in insulindependent diabetes mellitus,essential hypertension and cardiac hypertrophy[J].Eur J Pharm Sci,2000,11(4):299-306.DOI:10.1016/s0928-0987(00)00110-x.
• [26]Huggett RJ,Scott EM,Gilbey SG,et al.Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension[J].Circulation,2003,108(25):3097-3101.DOI:10.1161/01.CIR.0000103123.66264.FE.
• [27]Huggett RJ,Scott EM,Gilbey SG,et al.Disparity of autonomic control in type 2 diabetes mellitus[J].Diabetologia,2005,48(1):172-179.DOI:10.1007/s00125-004-1601-6.
• [28]Straznicky NE,Grima MT,Sari CI,et al.Neuroadrenergic dysfunction along the diabetes continuum:a comparative study in obese metabolic syndrome subjects[J].Diabetes,2012,61(10):2506-2516.DOI:10.2337/db 12-0138.
• [29]Vallbo AB,Hagbarth KE,Torebj??rk HE,et al.Somatosensory,proprioceptive,and sympathetic activity in human peripheral nerves[J].Physiol Rev,1979,59(4):919-957.DOI:10.115 2/physrev.1979.5 9.4.919.
• [30]Huggett RJ,Hogarth AJ,Mackintosh AF,et al.Sympathetic nerve hyperactivity in non-diabetic offspring of patients with type 2 diabetes mellitus[J].Diabetologia,2006,49(11):2741-2744.DOI:10.1007/s00125-006-0399-9.
• [31]Santulli G,Trimarco B,Iaccarino G.G-protein-coupled receptor kinase 2 and hypertension:molecular insights and pathophysiological mechanisms[J].High Blood Press Cardiovasc Prev,2013,20(1):5-12.DOI:10.1007/s40292-013-0001-8.
• [32]Santulli G,Lombardi A,Sorriento D,et al.Age-related impairment in insulin release:the essential role of β(2)-adrenergic receptor[J].Diabetes,2012,61(3):692-701.DOI:10.233 7/db11-1027.
• [33] Laakso M,Edelman SV,Brechtel G,et al.Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man.A novel mechanism for insulin resistance[J].J Clin Invest,1990,85(6):1844-1852.DOI:10.1172/JCI114644.
• [34]Grassi G,Dell'Oro R,Facchini A,et al.Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives[J].J Hypertens,2004,22(12):2363-2369.DOI:10.1097/00004872-200412000-00019.
• [35]Masuo K,Mikami H,Ogihara T,et al.Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young,nonobese Japanese population[J].Am J Hypertens,1997,10(1):77-83.DOI:10.1016/s0895-7061(96)00303-2.
• [36]Hausberg M,Mark AL,Hoffman RP,et al.Dissociation of sympathoexcitatory and vasodilator actions of modestly elevated plasma insulin levels[J].J Hypertens,1995,13(9):1015-1021.DOI:10.1097/00004872-199509000-00012.
• [37]Lansdown A,Rees DA.The sympathetic nervous systemin polycystic ovary syndrome:a novel therapeutic target?[J].Clin Endocrinol(Oxf),2012,77(6):791-801.DOI:10.1111/cen.12003.
• [38] Masuo K,Kawaguchi H,Mikami H,et al.Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation[J].Hypertension,2003,42(4):474-480.DOI:10.1161/01.HYP.0000091371.53502.D3.
• [39]Flaa A,Aksnes TA,Kjeldsen SE,et al.Increased sympathetic reactivity may predict insulin resistance:an 18-year follow-up study[J].Metabolism,2008,57(10):1422-1427.DOI:10.1016/j.metabol.2008.05.012.
• [40]Lembo G,Capaldo B,Rendina V,et al.Acute noradrenergic activation induces insulin resistance in human skeletal muscle[J].Am J Physiol,1994,266(2 Pt 1):E242-E247.DOI:10.1152/ajpendo.1994.266.2.E242.
• [41] Jamerson KA,Julius S,Gudbrandsson T,et al.Reflex sympathetic activation induces acute insulin resistance in the human forearm[J].Hypertension,1993,21(5):618-623.DOI:10.1161/01.hyp.21.5.618.
• [42]Mancia G,Bousquet P,Elghozi JL,et al.The sy mpathetic nervous system and the metabolic syndrome[J].J Hypertens,2007,25(5):909-920.DOI:10.1097/HJH.0b013e328048d004.
• [43]Landsberg L.Diet,obesity and hypertension:an hypothesis involving insulin,the sympathetic nervous system,and adaptive thermogenesis[J].Q J Med,1986,61(236):1081-1090.
• [44]Landsberg L.Insulin-mediated sympathetic stimulation:role in the pathogenesis of obesity-related hypertension(or,how insulin affects blood pressure,and why)[J].J Hypertens,2001,19(3 Pt 2):523-528.DOI:10.1097/00004872-200103001-00001.
• [45]Salman IM,Ameer OZ,Sattar MA,et al.Renal sympathetic nervous system hyperactivity in early streptozotocin-induced diabetic kidney disease[J].Neurourol Urodyn,2011,30(3):438-446.DOI:10.1002/nau.21007.
• [46]DiBona GF.The sympathetic nervous system and hypertension:recent developments[J].Hypertension,2004,43(2):147-150.DOI:10.1161/01.HYP.0000113047.47711.fa.
• [47]Jerums G,Premaratne E,Panagiotopoulos S,et al.The clinical significance of hyperfiltration in diabetes[J].Diabetologia,2010,53(10):2093-2104.DOI:10.1007/s00125-010-1794-9.
• [48]Huang WC,Fang TC,Cheng JT.Renal denervation prevents and reverses hyperinsulinemia-induced hypertension in rats[J].Hypertension,1998,32(2):249-254.DOI:10.1161/01.hyp.32.2.249.
• [49] Toblli JE,Cao G,Giani JF,et al.Long-term treatment with nebivolol attenuates renal damage in Zucker diabetic fatty rats[J].J Hypertens,2011,29(8):1613-1623.DOI:10.1097/HJH.0b013e328349064c.
• [50]de Oliveira TL,Lincevicius GS,Shimoura CG,et al.Effects of renal denervation on cardiovascular,metabolic and renal functions in streptozotocin-induced diabetic rats[J].Life Sci,2021,278:119534.DOI:10.1016/j.lfs.2021.119534.
• [51]Wang Y,Rijal B,Xu M,et al.Renal denervation improves vascular endothelial dysfunction by inducing autophagy via AMPK/mTOR signaling activation in a rat model of type 2 diabetes mellitus with insulin resistance[J].Acta Diabetol,2020,57(10):1227-1243.DOI:10.1007/s00592-020-01532-6.
• [52]Pan T,Guo JH,Ling L,et al.Effects of multi-electrode renal denervation on insulin sensitivity and glucose metabolism in a canine model of type 2 diabetes mellitus[J].J Vasc Interv Radiol,2018,29(5):731-738.e732.DOI:10.1016/j.jvir.2017.12.011.
• [53]Huo JY,Jiang WY,Zhang SG,et al.Renal denervation ameliorates cardiac metabolic remodeling in diabetic cardiomyopathy rats by suppressing renal SGLT2 expression[J].Lab Invest,2022,102(4):341-351.DOI:10.1038/s41374-021-00696-1.
• [54]Miroslawska AK,Gjessing PF,Solbu MD,et al.Metabolic effects two years after renal denervation in insulin resistant hypertensive patients.The Re-Shape CV-risk study[J].Clin Nutr,2021,40(4):1503-1509.DOI:10.1016/j.clnu.2021.02.027.
• [55]Schlaich MP,Hering D,Sobotka P,et al.Effects of renal denervation on sympathetic activation,blood pressure,and glucose metabolism in patients with resistant hypertension[J].Front Physiol,2012,3:10.DOI:10.3 3 89/fphys.2012.00010.
• [56]Somers VK,Anderson EA,Mark AL.Sympathetic neural mechanisms in human hypertension[J].Curr Opin Nephrol Hypertens,1993,2(1):96-105.DOI:10.1097/00041552-199301000-00015.
• [57]Manukyan M,Falkovskaya A,Mordovin V,et al.Favorable effect of renal denervation on elevated renal vascular resistance in patients with resistant hypertension and type 2 diabetes mellitus[J].Front Cardiovasc Med,2022,9:1010546.DOI:10.3 389/fcvm.2022.1010546.
• [58]Kandzari DE,Townsend RR,Kario K,et al.Safety andefficacy of renal denervation in patients taking antihypertensive medications[J].J Am Coll Cardiol,2023,82(19):1809-1823.DOI:10.1016/j.j acc.2023.08.045.
• [59] Kandzari DE,B??hm M,Mahfoud F,et al.Renal denervation in the presence of antihypertensive medications:six-month results from the randomized,blinded,sham-controlled SPYRAL HTN-ON MED trial[J].Lancet,2018,391(10137):2346-2355.DOI:10.1016/S0140-6736(18)31112-7.
• [60]Mahfoud F,Kandzari DE,Kario K,et al.Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs(SPYRAL HTN-ON MED):a randomised,sham-controlled trial[J].Lancet,2022,399(10336):1401-1410.DOI:10.1016/S0140-6736(22)01394-0.
• [61]Bytyqi V,Kannenkeril D,Schmid A,et al.Effect of renal denervation on glucose metabolism in hypertensive patients with and without chronic kidney disease:a post hoc analysis[J].Clin Kidney J,2025,18(7):sfaf184.DOI:10.1093/ckj/sfaf184.
• [62]国家放射与治疗临床医学研究中心,苏州工业园区东方华夏心血管健康研究院高血压介入治疗工作委员会,《经皮去肾神经术治疗高血压临床路径中国专家共识(2025版)》专家组.经皮去肾神经术治疗高血压临床路径中国专家共识(2025版)[J].中国介入心脏病学杂志,2025,33(9):481-490.DOI:10.3969/j.issn.1004-8812.2025.09.001.
• [63]苏州工业园区东方华夏心血管健康研究院高血压介入治疗工作委员会,《经皮去肾神经术治疗高血压中国专家科学声明》专家组.经皮去肾神经术治疗高血压中国专家科学声明[J].中国介入心脏病学杂志,2023,31(12):881-893.DOI:10.3969/j.issn.1004-8812.2023.12.001.